A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.James R. Berenson, Sal Bevivino, Russell Mapes et al.|Blood|2005Cited by 11